Google News • 1/22/2026
Johnson & Johnson (J&J) reported its fourth-quarter and full-year 2025 earnings, highlighting a strategy focused on leading in the cancer fight, with oncology sales exceeding $25 billion. J&J's MedTech sales increased by 7.5% in Q4. Despite facing challenges such as tariffs and a pricing deal from Trump, J&J anticipates 2026 profits to surpass Wall Street estimates.
Advertisement
Stories gain Lindy status through source reputation, network consensus, and time survival.


